RxDoctor Payments Data

Jill Gibson, MD

Obstetrics & Gynecology · Covington, LANPI 1417124736

Payments from drug & device makers

$5,023in general payments, 2019–2025

Across 331 payments — averaging $15.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$979
  • Avion Pharmaceuticals$891
  • Evofem Biosciences, Inc.$660
  • Exeltis, USA Inc.$626
  • Mayne Pharma Commercial LLC$318
  • Aspira Women's Health Inc$278
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$5,023100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,023 in reported general payments places this provider in the 85th percentile of 608 obstetrics & gynecology providers in Louisiana.

See all obstetrics & gynecology providers in Louisiana

Medicare billing

Part B allowed, 2024
$42,610
Medicare patients
183
Services billed
430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol405$14,937
PremarinEstrogens, Conjugated16$6,929
ProgesteroneProgesterone, Micronized221$5,564
DottiEstradiol41$3,830
Estradiol (Twice Weekly)Estradiol39$2,629
ImvexxyEstradiol12$2,445
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet26$1,243
ValacyclovirValacyclovir Hcl51$1,227
FyavolvNorethindrone Ac/Eth Estradiol16$1,032
Estradiol (Once Weekly)Estradiol21$1,017
Medroxyprogesterone Acetate36$775
Raloxifene Hcl16$531
Clobetasol Propionate14$403
Nystatin32$360
VolneaDesog-E.Estradiol/E.Estradiol22$334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$99$6,92916 claims
Therapeuticsmd, Inc.Imvexxy$157$2,44512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 608 obstetrics & gynecology providers in Louisiana.

Other obstetrics & gynecology in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →